MUC1 and laryngotracheoesophageal cleft: The present study aimed [1] to serially analyze KL-6 in IPF patients after 24 months of Nintedanib and [2] to investigate its biomarker potential in patients with IPF-LC with respect to fHP, PF-AD patients, and healthy controls.